Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for ARQT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 39.31M
March 31, 2026 26.99M
December 31, 2025 -5.625M
September 30, 2025 -32.56M
June 30, 2025 -65.49M
March 31, 2025 -110.94M
December 31, 2024 -112.16M
September 30, 2024 -167.65M
June 30, 2024 -176.95M
March 31, 2024 -198.32M
December 31, 2023 -247.06M
September 30, 2023 -261.88M
June 30, 2023 -285.59M
March 31, 2023 -281.08M
Date Value
December 31, 2022 -257.72M
September 30, 2022 -238.36M
June 30, 2022 -211.55M
March 31, 2022 -185.40M
December 31, 2021 -174.63M
September 30, 2021 -155.02M
June 30, 2021 -148.30M
March 31, 2021 -138.23M
December 31, 2020 -113.03M
September 30, 2020 -99.02M
June 30, 2020 -75.78M
March 31, 2020 -58.17M
December 31, 2019 -44.24M
September 30, 2019 -31.98M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 160.32M
Insmed, Inc. -778.92M
Emergent BioSolutions, Inc. 97.70M
Exelixis, Inc. 1.183B
Vertex Pharmaceuticals, Inc. 4.293B